PT - JOURNAL ARTICLE AU - Vasileios Papadopoulos AU - Marios-Vasileios Koutroulos AU - Dimitra-Georgia Zikoudi AU - Stefania-Aspasia Bakola AU - Peny Avramidou AU - Ntilara Touzlatzi AU - Dimitrios K. Filippou TI - Acute Metabolic Emergencies in Diabetes and COVID-19: a systematic review and meta-analysis of case reports AID - 10.1101/2021.01.10.21249550 DP - 2021 Jan 01 TA - medRxiv PG - 2021.01.10.21249550 4099 - http://medrxiv.org/content/early/2021/01/11/2021.01.10.21249550.short 4100 - http://medrxiv.org/content/early/2021/01/11/2021.01.10.21249550.full AB - Introduction COVID-19 is associated with DKA (Diabetic Ketoacidosis), HHS (Hyperglycaemic Hyperosmolar State) and EDKA (Euglycaemic DKA). High mortality has been observed in COVID-19-related diabetic ketoacidosis; however, evidence is scarce.Patients and Methods A systematic literature review was conducted using EMBASE, PubMed/Medline, and Google Scholar from January to December 2020 to identify all case reports describing DKA, HHS, and EDKA, in COVID-19 patients. The Joanna Briggs Institute critical appraisal checklist for case reports was used for quality assessment. Univariate and multivariate analysis assessed correlations of study origin, combined DKA/HHS, age, BMI, HbA1c, administered antidiabetics, comorbidities, symptoms onset, disease status, CRP, ferritin, d-dimers, glucose, osmolarity, pH, bicarbonates, ketones, lactates, β-hydroxybutyric acid, anion gap, and acute kidney injury (AKI) with outcome.Results From 312 identified publications, 41 including 71 cases analyzed qualitatively and quantitatively. Multivariate analysis demonstrated that COVID-19 disease status 4 (P<0.001), AKI (P<0.001), pH ≤7.12 (P=0.032), and osmolarity ≥324 (P=0.034), are all independently correlated with death. COVID-19 Disease Status 4 (P=3•10−8), combined DKA/HHS (P=0.021), and AKI (P=0.037) are independently correlated with death.Conclusion COVID-19 intertwines with acute metabolic emergencies in diabetes leading to increased mortality; key determinants are critical COVID-19 illness, co-presence of ketoacidosis and hyperosmosis and AKI.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was recieved. ENARGEIA Medical Ltd, Xanthi, Greece, will compensate for any publication costs in the future.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Xanthi General Hospital Scientific CommitteeAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to the manuscript will be available at https://www.enargeia.eu/.